10:31 AM EST - Antibe Therapeutics Inc. : Highlights that a research article has been published in the British Journal of Pharmacology on the successful Phase 2B GI safety trial for its lead drug, ATB-346. BJP is considered one of the world’s pre-eminent scientific journals in pharmacology. Antibe Therapeutics Inc.
shares V.ATE are trading up $0.005 at $0.33.
